Evidence map›Paper›PMID 40888883›Full record

ReviewDermatologie (Heidelberg, Germany)2025

[Lupus erythematosus].

Patrick-Pascal Strunz, Marc Schmalzing, Matthias Goebeler, Astrid Schmieder

Abstract readReviewEnglish Abstract
PubMed Publisher
In one paragraph

Review in Dermatologie (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Patrick-Pascal StrunzMedizinische Klinik und Poliklinik II, Schwerpunkt für Rheumatologie/Klinische Immunologie, Universitätsklinikum Würzburg, Oberdürrbacher Str. 6, 97080, Würzburg, Deutschland.
Marc SchmalzingMedizinische Klinik und Poliklinik II, Schwerpunkt für Rheumatologie/Klinische Immunologie, Universitätsklinikum Würzburg, Oberdürrbacher Str. 6, 97080, Würzburg, Deutschland.
Matthias GoebelerKlinik für Dermatologie und Venerologie, Universitätsklinikum Würzburg, Josef-Schneider-Str. 2, 97080, Würzburg, Deutschland.
Astrid SchmiederKlinik für Dermatologie und Venerologie, Universitätsklinikum Würzburg, Josef-Schneider-Str. 2, 97080, Würzburg, Deutschland. Schmieder_A@ukw.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cutaneous lupus erythematosus (CLE) comprises a heterogeneous spectrum of autoimmune dermatoses. Four main forms are distinguished: acute (ACLE), subacute (SCLE), intermediate (ICLE), and chronic CLE (CCLE). Epidemiological studies show that the overall risk of developing systemic lupus erythematosus (SLE) is highest within the first 3 years following diagnosis of CLE. Therefore, patients with newly diagnosed CLE should be closely monitored for systemic symptoms, especially in the first few years following CLE diagnosis. Therapy of CLE includes both topical and systemic approaches. Treatment of SLE with organ and cutaneous manifestation should ideally be treated in close cooperation with an internal medicine rheumatologist. The overall therapeutic landscape of lupus erythematosus in increasingly moving toward personalized approaches.

Indexed as

Lupus Erythematosus, CutaneousHumansImmunosuppressive AgentsLupus Erythematosus, SystemicImmunosuppressive AgentsCutaneous lupus erythematosusPrecision medicineSystemic administrationSystemic lupus erythematosusTopical administration

Identifiers

PMID40888883

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.